CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...

CVS Health Corporation is a vertically integrated healthcare corporation in the United States. The company owns a leading ...

CVS Caremark, Express Scripts ... based on a subset of medications that represent less than 2% of what our health plans spend on medications in a year.” Express Scripts sued the FTC in September ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

CVS Health Corporation (NYSE ... owning a healthcare benefits business (Aetna), a pharmacy-benefits manager (Caremark), an in-home evaluation business (Signify Health) and in-home primary care ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...